GlassScriptPhysician profile
Laura A Cunningham
NPI 1841735388
$4,193.84
in general payments reported to CMS, 2019-2025
24 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,644 · 2022: $438 · 2023: $330 · 2024: $604 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $1,522.65 | 2021-2022 | |
| Glaxosmithkline, LLC. | $457.16 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $420.65 | 2021-2025 | Dupixent |
| Genzyme Corporation | $392.26 | 2021-2025 | |
| Dexcom, INC. | $152.65 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $135.06 | 2022-2025 | Propel |
| Abbvie INC. | $125.93 | 2025 | |
| Optinose US, INC. | $125.41 | 2021-2024 | |
| Exact Sciences Corporation | $119.84 | 2025 | The Cologuard Plus Collection Kit |
| Smith+Nephew, INC. | $107.96 | 2025 | Tula, Halo |
| Astrazeneca Pharmaceuticals LP | $88.13 | 2023-2025 | Tezspire, Fasenra |
| Lucid Diagnostics INC. | $86.75 | 2024 | |
| Boston Scientific Corporation | $79.92 | 2024 | Wavewriter Alpha Prime 16 |
| Melinta Therapeutics, LLC | $62.05 | 2024-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Hologic Sales and Service, LLC | $55.32 | 2023-2024 | Coolseal Generator |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $49.86 | 2023 | Xpress Ent Dilation System |
| Merck Sharp & Dohme LLC | $35.44 | 2021-2022 | |
| Genentech USA, INC. | $34.48 | 2025 | Polivy, Xolair |
| Jazz Pharmaceuticals INC. | $33.64 | 2024 | |
| Olympus America INC. | $29.37 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.34 | 2022-2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $23.96 | 2025 | |
| Insmed, INC. | $15.64 | 2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $13.37 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.